Patients with non-segmental vitiligo receiving upadacitinib continued to show repigmentation through 76 weeks of follow-up, according to a Dermatology Times report on long-term extension data.

The finding extends the durability profile of upadacitinib, an oral selective Janus kinase 1 (JAK1) inhibitor under investigation for vitiligo. The published headline confirms continued response without specifying the magnitude of repigmentation at the Week 76 cutoff.

What does Week 76 actually measure?

Week 76 represents a maintenance-phase timepoint roughly 12 to 14 months beyond typical primary endpoint windows in late-stage vitiligo programs. Sustained response at this interval directly addresses one of the field's central questions: whether repigmentation achieved during induction therapy persists past the first year of continuous oral treatment, or whether melanocyte autoimmunity resumes once the drug is removed.

Non-segmental vitiligo, the most common disease subtype, typically shows symmetric, bilateral distribution and tends to progress over time. The segmental variant follows a dermatomal pattern and tends to stabilize earlier, which is why systemic programs have concentrated on the non-segmental form.

How does upadacitinib compare with existing options?

Topical ruxolitinib cream, a JAK1/JAK2 inhibitor, became the first U.S. Food and Drug Administration-approved repigmentation therapy for non-segmental vitiligo in 2022. Its approval validated melanocyte restoration as a clinically meaningful endpoint and established a regulatory pathway for JAK inhibition in the disease.

Oral upadacitinib offers systemic exposure, which investigators have hypothesized could reach lesions across larger body surface areas — including acral sites that respond poorly to topical therapy. Phase 3 data for the program were reported previously, and the Week 76 update now confirms that response is durable.

Why durability data carry weight

Relapse after treatment discontinuation has emerged as a defining challenge for vitiligo therapy. Across the JAK-inhibitor class, repigmentation achieved during active treatment often regresses once the drug is stopped, reflecting the autoimmune substrate of the disease. Long-term extension cohorts provide the first evidence on whether continuous oral dosing can hold disease activity in check past 12 months.

The Dermatology Times report positions the Week 76 finding as a durability signal rather than a fresh efficacy readout, suggesting investigators are tracking the same responders who benefited earlier in the program.

What the safety picture looks like

Long-term safety remains the central open question for systemic JAK1 inhibition in vitiligo, where the typical patient population skews younger and has fewer comorbidities than rheumatologic patients who first received these agents. Upadacitinib's existing label — drawn from atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, Crohn disease, and ulcerative colitis experience — carries class warnings for thromboembolism, malignancy, major adverse cardiovascular events, and mortality.

Whether the vitiligo-specific extension cohort reproduces that safety profile at acceptable rates will shape any future regulatory submission. Dermatology readers should expect the full Week 76 dataset to surface in peer-reviewed form before oral upadacitinib can be formally positioned in vitiligo treatment algorithms.

What's next

Clinicians managing non-segmental vitiligo should anticipate the complete Week 76 analysis in a peer-reviewed journal, with adverse event rates stratified by indication. Until then, the report signals ongoing follow-up but does not yet define a clinical role for systemic upadacitinib in vitiligo care.